Industrial Approach to Determine the Relative Contribution of Seven Major UGT Isoforms to Hepatic Glucuronidation

The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer

Giuseppe Toffoli, Erika Cecchin, Giuseppe Corona et al. · Journal of Clinical Oncology · 2006 · 337 citations · Full text

Medicine, Oncology, Pharmacology +17

HUMAN UDP-GLUCURONOSYLTRANSFERASES: ISOFORM SELECTIVITY AND KINETICS OF 4-METHYLUMBELLIFERONE AND 1-NAPHTHOL GLUCURONIDATION, EFFECTS OF ORGANIC SOLVENTS, AND INHIBITION BY DICLOFENAC AND PROBENECID

Verawan Uchaipichat, Peter I. Mackenzie, Xiao-Hui Guo et al. · Drug Metabolism and Disposition · 2004 · 334 citations

Life Sciences, Biochemistry, Pharmacology +14

SELECTIVITY OF SUBSTRATE (TRIFLUOPERAZINE) AND INHIBITOR (AMITRIPTYLINE, ANDROSTERONE, CANRENOIC ACID, HECOGENIN, PHENYLBUTAZONE, QUINIDINE, QUININE, AND SULFINPYRAZONE) “PROBES” FOR HUMAN UDP-GLUCURONOSYLTRANSFERASES

Verawan Uchaipichat, Peter I. Mackenzie, David J. Elliot et al. · Drug Metabolism and Disposition · 2005 · 248 citations

Medicine, Biochemistry, Pharmacology +12

Quantitative Analysis of UDP-Glucuronosyltransferase (UGT) 1A and UGT2B Expression Levels in Human Livers

Takeshi Izukawa, Miki Nakajima, Ryoichi Fujiwara et al. · Drug Metabolism and Disposition · 2009 · 231 citations

Life Sciences, Biochemistry, Molecular Biology +13

The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and<i>in vitro–in vivo</i>extrapolation of drug clearance and drug-drug interaction potential

John O. Miners, Peter I. Mackenzie, Kathleen Knights · Drug Metabolism Reviews · 2009 · 226 citations

Pharmacy, Pharmacokinetics, Pharmacology +17